The Mutua Madrileña Foundation in its XI Call for Research Grants, has selected a project aimed at personalizing the treatment of lung cancer led by the team leader of the ICO-IDIBELL chemoresistance group, Alberto Villanueva.

The project is based on the personalization of cancer treatments for non-small cell lung (NSCLC) by the generation of mouse models of orthotropic individualized or orthoxenografts. This is a multidisciplinary project with the collaboration of basic and clinical researchers, ICO IDIBELL and the University Hospital of Bellvitge.